Five Prime Therapeutics Inc. (FPRX)

13.75
NASDAQ : Health Technology
Prev Close 13.75
Day Low/High 0.00 / 0.00
52 Wk Low/High 13.41 / 48.87
Avg Volume 322.10K
Exchange NASDAQ
Shares Outstanding 35.58M
Market Cap 483.52M
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Five Prime Therapeutics To Announce Second Quarter 2018 Financial Results And Host Conference Call On August 8

Five Prime Therapeutics To Announce Second Quarter 2018 Financial Results And Host Conference Call On August 8

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its second quarter 2018 financial results on Wednesday, August 8, 2018,...

Interesting FPRX Put And Call Options For August 17th

Interesting FPRX Put And Call Options For August 17th

Investors in Five Prime Therapeutics, Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FPRX options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Five Prime Therapeutics To Present At Goldman Sachs 39th Annual Global Healthcare Conference

Five Prime Therapeutics To Present At Goldman Sachs 39th Annual Global Healthcare Conference

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Goldman Sachs 39th...

Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster At The 2018 ASCO Annual Meeting

Five Prime Therapeutics Presents Bemarituzumab Trial-in-Progress Poster At The 2018 ASCO Annual Meeting

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced that a poster titled "FIGHT: A Phase 3 Randomized, Double-Blind, Placebo...

Five Prime Therapeutics To Present At Jefferies 2018 Global Healthcare Conference

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Francis Sarena, Chief Strategy Officer, will present at the Jefferies 2018 Global...

Five Prime Therapeutics Appoints Bryan Irving, Ph.D., As Chief Scientific Officer

Five Prime Therapeutics Appoints Bryan Irving, Ph.D., As Chief Scientific Officer

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Bryan Irving, Ph.

Five Prime Therapeutics Announces First Quarter 2018 Financial Results

Five Prime Therapeutics Announces First Quarter 2018 Financial Results

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported financial results for the fiscal...

Five Prime To Present At 2018 ASCO Annual Meeting

Five Prime To Present At 2018 ASCO Annual Meeting

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that it will present two posters during the 2018 American Society of...

Five Prime Therapeutics To Announce First Quarter 2018 Financial Results And Host Conference Call On May 8

Five Prime Therapeutics To Announce First Quarter 2018 Financial Results And Host Conference Call On May 8

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2018 financial results on Tuesday, May 8, 2018,...

Five Prime Therapeutics Initiates Patient Dosing In Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150

Five Prime Therapeutics Initiates Patient Dosing In Phase 1 Trial Of Novel First-in-Class B7-H4 Antibody FPA150

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that it initiated patient dosing in its Phase 1...

Five Prime Therapeutics Announces Oral Presentation On FPA150 At The 2018 AACR Annual Meeting

Five Prime Therapeutics Announces Oral Presentation On FPA150 At The 2018 AACR Annual Meeting

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Charles D.

First Week of FPRX May 18th Options Trading

First Week of FPRX May 18th Options Trading

Investors in Five Prime Therapeutics, Inc saw new options become available this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the FPRX options chain for the new May 18th contracts and identified one put and one call contract of particular interest.

Five Prime Therapeutics Licenses New Target To UCB Originating From Its Proprietary Protein Discovery Platform

Five Prime Therapeutics Licenses New Target To UCB Originating From Its Proprietary Protein Discovery Platform

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced UCB has elected to exclusively...

Relative Strength Alert For Five Prime Therapeutics

Relative Strength Alert For Five Prime Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Five Prime Therapeutics Announces Executive Change

Five Prime Therapeutics Announces Executive Change

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that Marc Belsky, Senior Vice...

Five Prime Therapeutics To Present At Cowen And Company 38th Annual Health Care Conference

Five Prime Therapeutics To Present At Cowen And Company 38th Annual Health Care Conference

Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer,...

Five Prime Announces Fourth Quarter And Full Year 2017 Financial Results

Five Prime Announces Fourth Quarter And Full Year 2017 Financial Results

Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today provided a corporate update and reported...

Five Prime Therapeutics Announces Closing Of Upsized Public Offering

Five Prime Therapeutics Announces Closing Of Upsized Public Offering

Underwriters Fully Exercise Option to Purchase Additional Shares

Five Prime Therapeutics Announces $25 Million Payment By Bristol-Myers Squibb For Cabiralizumab Development Milestone

Five Prime Therapeutics Announces $25 Million Payment By Bristol-Myers Squibb For Cabiralizumab Development Milestone

Initiation of Phase 2 study of Cabiralizumab plus Opdivo in advanced pancreatic cancer

Five Prime Therapeutics Submits Investigational New Drug Application For Novel B7-H4 Antibody FPA150

Five Prime Therapeutics Submits Investigational New Drug Application For Novel B7-H4 Antibody FPA150

Dual mechanism of action blocks a T cell checkpoint pathway and delivers enhanced ADCC against B7-H4-expressing tumor cells

TheStreet Quant Rating: D (Sell)